Complex Erdheim-Chester disease associating rectal adenocarcinoma and breast cancer

Mihaela Guţu2a, Mihai Danciu1,2b, Mihai Guţu1,2a, Mihai Marinca1,3, Roxana Livadariu2c, Răzvan Țepordei1,2d, Mioara Nitu2e, Tudor Cozma1,2d, Manuela Ursaru1,2e, Lucian Miron1,3, Cipriana Ștefănescu1,2a

5a Gr. T. Popa” University of Medicine and Pharmacy Iasi, Romania, 2 University Emergency Hospital “Sf. Spiridon” Iasi, Romania, a Nuclear Medicine Department, b Pathology Department, c General Surgery Department, d Orthopaedics and Traumatology Department, e Radiology Department, 3 Regional Oncology Institute, Iasi, Romania

Abstract

Erdheim-Chester Disease (ECD) is a rare form of non-Langerhans’ cell histiocytosis (non-LCH). It is characterized by the excessive production of histiocytes. We present the case of a 63 year-old Caucasian woman with ECD, with a history of breast cancer (diagnosed in 2006) and rectal cancer (diagnosed in 2013). Most probably, the initial ECD manifestation occurred within the next 5 years after mastectomy in the soft tissues adjacent to the scar. Recently it became manifest in a different localization (meta-diaphysis of long bones), while the other possible sites like the lungs, central nervous system and pituitary gland show minimal involvement with no specific clinical manifestation yet. Shortly after the bone manifestations were detected, she developed an invasive rectal adenocarcinoma. The ECD diagnosis was based on bone scintigraphy, radiography and immunohistochemistry examination.

Keywords: Erdheim-Chester disease, breast cancer, rectal adenocarcinoma, scintigraphy, immunohistochemistry

Introduction

Histiocytic disorders are a group of diseases that occur when there is an overproduction of tissue macrophage cells known as histiocytes. The Erdheim-Chester Disease (ECD) (also known as polyostotic sclerosing histiocytosis) is a rare form of non-Langerhans cell histiocytosis (non-LCH) and until 2015 around 500 cases were reported [1]. Individuals affected by this disease are typically adults aged 50 to 70 years [2] but also 30 and 40 year-old cases were reported [3]. Males and females are almost equally affected, no clear gender-related differences in prevalence exist [2]. To our knowledge, no cases diagnosed with ECD that associate a malignancy (much less two) were yet reported; few cases were reported as ECD of the breast [4]. The ECD is characterized by the excessive production of histiocytes and so far it has no known etiology [5]. Sites of involvement include lung, bone, skin, retro-orbital tissue, central nervous system, pituitary gland, retroperitoneum and pericardium [1, 2]. The diagnosis is based on radiological and histological findings [2]; some authors suggest that bone scintigraphy could be the gold standard to assess bone involvement [6]. The
radiological findings are diffuse bone sclerosis that occurs bilaterally and symmetrically in the meta-diaphysis regions of the long bones [2, 7]; bone scintigraphy notes increased tracer uptake particularly involving meta-diaphysis of the femurs and tibias [8]. The histological changes include tissue infiltration with lipid granulomas composed of foamy CD68-positive but CD1a-negative macrophages, in contrast to Langerhans cells. These macrophages are also usually negative for S-100 protein but may occasionally be weakly positive [9, 10].

We report a patient with a typical pattern of bone-generalized ECD, later proven to have mammary involvement, which was associated with breast and rectal cancer. The diagnosis was based on bone scintigraphy, clinical identification of a breast lump and bone biopsies (histological/immunohistochemical findings). Mammary involvement by ECD is an extremely rare condition, which should be differentiated from benign or malignant tumors. Distinctive histological features plus clinical and scintigraphic information are needed to achieve a correct diagnosis [2].

Case report

A 63 year-old Caucasian woman with a complex medical history, had addressed to Nuclear Medicine Department for investigation of a recently onset knee pain.

She was diagnosed at age 55 (December 2006) with a nodule in the upper outer quadrant of her left breast. Quadrantectomy with axillary dissection was performed, and pathology showed invasive carcinoma of no specific type (IC-NST) with ductal carcinoma in situ (DCIS); nine of a total 25 excised lymph nodes were positive for tumor cells (TNM stage IIIA).

Immunohistochemistry revealed intensely positive estrogen (90% of tumor cells) and progesterone receptors (75%) and negative (1+) Her-2/neu status. The patient was administered 6 cycles of adjuvant chemotherapy (standard FE90C protocol) and radiation therapy (60 Co, a total dose of 60 Gy in 30 fractions on the tumor bed, left breast and axilla), then continued on hormone therapy (anastrozole 1mg/day). In February 2008, a breast ultrasound showed a 19-mm mass underneath the surgical scar. Pathology exam of the lumpectomy specimen showed a IC-NST with foci of DCIS and mucinous carcinoma. After 3 cycles of paclitaxel monochemotherapy, a 40-mm cyst-like mass of DCIS was removed through left Madden modified radical mastectomy in April 2008. She was then administered another 4 cycles of chemotherapy (docetaxel plus gemcitabine) and continued on anastrozole for a total of 5 years. During follow-up (January 2012), a clinical examination identified two 30/20-mm tumors on the thoracic wall and basis of the right axilla, respectively, which were concomitantly excised. Pathology report diagnosed a multicentric benign fibrous histiocytoma (BFH) – a subtype of LCH. Resection was needed in March 2012 and again in January 2013, with the same diagnosis of BFH. Starting July 2013, she complained of abdominal pain, weight loss and fatigue, and also bilateral knee pain. A digital rectal examination (October 2013) identified a tumor at 30-40 mm from the anal verge, clinically staged as T3N2M0 by chest and abdominal CT-scans; biopsy was diagnostic for well differentiated rectal adenocarcinoma.

A bone biopsy was performed from the distal femoral lesions. All tissue specimens were routinely processed using formalin fixation and paraffin embedding. Additionally, after fixation, bone tissue specimens taken from inferior metaphysis of the right femur were decalcified. Five-micron tissue sections were examined under routine – hematoxylin-eosine (HE) and trichromatic – staining. Immunohistochemistry used monoclonal antibodies anti-CD68 (clone PG-M1, Dako), anti-CD1a (clone 010, Dako), anti-Cytokeratin (clone AE1/AE3, Dako) and polyclonal antibody anti-S100 protein (Dako). To exclude a breast cancer metastasis to the bone, estrogen receptor (clone 1D5, Dako) and progesterone receptor (clone PgR 636, Dako) staining was also used. Tissue pretreatment included heat-induced epitope retrieval in citrate buffer solution, and detection was done with an EnVision kit.
Discussion

The almost symmetrically distributed bone pain (especially in the knees) that could have suggested the ECD diagnosis – as described in other cases [7] – had appeared 2 years later. In this context the radiology (knee X-ray) revealed a symmetrical femoral metadiaphysis fibrosis (also common in ECD) [2, 6] (Figure 1).

Fig. 1. Knee X-ray showing bilateral and symmetrical bone condensation along the femoral metadiaphysis

The long bones fibrotic reaction was also seen on the left proximal and right distal humeral metaphysis and the left greater trochanter (Figure 2). Brain MRI showed thickening in the upper two thirds of pituitary stem, adjacent to the posterior optical chiasm. Since pathogenesis, natural history and lesions are very similar for LCH and non-LCH, both showing LCH multisystem involvement and a possible abnormality in the common CD34 progenitor cell [11], a bone biopsy and microscopic re-examination of soft tissue samples biopsied from the left axillary region and anterior thoracic region in 2012, with subsequent tissue processing and immunohistochemistry were done for differential diagnosis of LCH, EDC, RDD and bone metastasis. The breast tissue examination identified a fibro-histiocytic proliferation with numerous foamy cells, some multinucleated and Touton giant cells, surrounded by lymphocytes. Rare mitotic figures were observed; architecture was focally storiform (similar to that of dermatofibrosarcoma). In the periphery, the tumor infiltrated the skeletal muscle and adipose tissue. Breast ECD is otherwise a rarely described localization [4, 12], ours being only the seventh such case report to our knowledge [13]. Microscopic examination of the bone biopsy revealed the replacement of the fatty marrow by fibrosis (Figure 3E) and foamy cells: nests of large cells, with small central nuclei and finely granular, pale eosinophilic cytoplasm. The ECD is characterized by xanthomatous or xanthogranulomatous infiltration of tissues by foamy histiocytes, "lipid-laden" macrophages, or histiocytes, surrounded by fibrosis [1] (Figure 3A). No multinucleated or Touton giant cells were identified in our sections.

While ECD and RDD could be differentiated pathologically (lack of emperipolesis) or clinically (no massive lymphadenopathy) [14], immunohistochemistry performed on bone marrow (or soft) tissue is essential in distinguishing Langerhans cells from non-Langerhans histiocytes. Immunohistochemical reassessment of the breast lesion revealed the following patterns: CD68 (+), CD1a (−), S100 (−), and CD68 (+), CD1a (−), S100 (+/−), respectively. The initial diagnosis (cellular BFH) was reconsidered as
non-LCH. The similar immunohistochemical profile in the bone – CD68 (+), CD1a (-) [2] and S100 (slightly positive) [10] – also supported the non-LCH type of bone proliferating histiocytes. The mild and focal positivity of S100 in histiocytes and the absence of emperipolesis in those histiocytes expressing S100 protein rule out the diagnosis of RDD. The negative staining for antibodies against cytokeratin (AE1/AE3 cocktail), estrogen (ER) and progesterone receptors (PgR) excluded a breast cancer metastasis. CD1a was negative in foamy histiocytes (Figure 3B), S100 was focally positive in foamy histiocytes and adipocytes (Figure 3C), and CD68 was positive in all foamy histiocytes (Figure 3D). Histological aspects and immunohistochemical profile of all lesions were highly consistent with the diagnosis of ECD.

It is important to remember that between first surgery and the soft tissue recurrence, our patient underwent chemo-, radio- and endocrine therapy. In this context, one might wonder whether the primary breast tumor could have also contained occult foci of ECD in the comedo type areas. As a result of radiotherapy [12] and/or the systemic treatments [15] these might have slowly evolved before becoming clinically evident. Radiotherapy has proven high rates of local control and symptomatic improvement in LCH, including some ECD patients [16, 17]. Chemotherapeutic agents have not been reliably evaluated as possible treatment for either ECD or LCH. Hormonal therapy for breast cancer is interfering with bone metabolism and might slow down the evolution of ECD [18].

Fig. 2. Whole body bone scintigraphy. High uptake on long bones: distal femoral diaphysis, tibiae diaphysis and metaphysis spearing the epiphysis. Other pathological uptakes can be seen on left clavicle, right maxilla, bilateral radial and ulnar diaphysis and metaphysis.
The initial manifestation of the ECD in this case was a focal breast soft tissue lesion. Another interesting fact is that, although multi-systemic infiltration of critical organ exists, it is not yet clinically manifest, despite the high osseous uptake of the Tc99m-hydroxy-bisphosphonate and the time passed from the first histological manifestation. While we consider the rectal adenocarcinoma to be a purely coincidental comorbidity, to our knowledge, this is the first published case of ECD associated with breast and rectal cancer. The patient is now following neoadjuvant chemo-radiotherapy. Decisions on further treatment will be made after radical surgery for rectal cancer. Not the least important of these decisions is the one on interferon therapy (the currently accepted treatment in ECD and other types of histiocytosis). Whether this should be initiated right away (should the clinical condition permit), deferred for a 1- or 2-year interval or forgone altogether (given the potential negative impact of immune system modulation on residual cancer cells) remains a matter of discussion.
Conclusion

ECD is a rare disease and its clinical manifestation could be very unspecific in oncological context. Bone scintigraphy (more sensitive than radiography) could be the starting point for ECD diagnosis, and should be followed by pathology examination and immunohistochemical tests. Specific features of this particular patient are: breast cancer history, ECD emerging in the breast soft tissue adjacent to postsurgical scars and association of a rectal adenocarcinoma. This case could make a point for routine ECD-specific immunohistochemical tests, at least in selected cases of breast cancer with local recurrence alone.

References